

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083069 A3

(51) International Patent Classification⁷: **A61K 39/02**,
G01N 33/554

503 Robert Grant Avenue, Silver Spring, MD 20910-7500 (US).

(21) International Application Number: PCT/US02/11379

(72) Inventors; and

(22) International Filing Date: 12 April 2002 (12.04.2002)

(75) Inventors/Applicants (for US only): **CHING, Wei-Mei** [US/US]; 8014 Whittier Blvd., Bethesda, MD 20817 (US). **KELLY, Daryl, J.** [US/US]; 12230 Flint Ridge Road, Newark, OH 43054 (US). **DASCH, Gregory, A.** [US/US]; 5473 Seville Lane, Stone Mountain, GA 30087 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/283,373 13 April 2001 (13.04.2001) US

(74) Agent: **OFFICE OF COUNSEL (CODE 00L)**; Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500 (US).


(71) Applicant (for all designated States except US): **UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY** [US/US]; Thomas Mc Donnell, Patent Counsel of the Navy, Office of Counsel (Code 00L),

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: RECOMBINANT PROTEINS OF ORIENTIA TSUTSUGAMUSHI

Genomic DNA of *O. tsutsugamushi* (Karp)



(57) Abstract: A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, *Orientia tsutsugamushi* or the karp, kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious strain similarity (i.e. a Karp-like, Kato-like or Gilliam-like strain) based on its strength of reaction toward a truncated protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects.

WO 02/083069 A3



MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

7 August 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.